Alpha-Synuclein PMCA Fluorescence for PD-MSA Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Parkinson's disease (PD) and multiple system atrophy (MSA) are not specific and sensitive enough to distinguish between the two conditions, leading to misdiagnosis and inadequate treatment.
Innovation Solution
A method using protein misfolding cyclic amplification (PMCA) with a pre-incubation mixture containing a monomeric αS substrate, buffer, salt, and indicator, followed by multiple incubation cycles and fluorescence detection to differentiate PD and MSA based on fluorescence emission intensity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for PD and MSA, then the diagnostic process is simple, but the measurement precision and reliability are insufficient leading to misdiagnosis
Solution Approach 1:
The patent uses misfolded alpha-synuclein aggregates as an intermediary biomarker to indirectly diagnose PD and MSA. Instead of directly detecting disease presence, the method detects aggregated protein forms in biological samples, which serve as mediators indicating disease state. This intermediary approach enables high-precision differentiation between PD and MSA through distinct aggregation patterns.
Solution Approach 2:
The patent replaces conventional mechanical/clinical diagnostic methods with a biochemical detection system. Instead of relying on physical examination and imaging, the invention uses in vitro aggregation assays with fluorescence detection to substitute traditional diagnostic mechanics with molecular-level biochemical measurements, achieving superior diagnostic precision.
2Measurement precision
If PMCA method is used to detect misfolded alpha-synuclein, then the measurement precision is high, but the detection difficulty increases due to low concentrations in biological samples
Solution Approach 1:
The patent applies preliminary action by performing in vitro aggregation of misfolded alpha-synuclein before detection. The method pre-concentrates and pre-organizes the target aggregates through controlled incubation conditions, transforming trace amounts of soluble misfolded protein into detectable aggregated forms. This preliminary aggregation step simplifies subsequent detection by creating abundant, easily measurable targets from originally scarce analytes.
Solution Approach 2:
The patent utilizes parameter changes by altering physical-chemical conditions (pH, temperature, ionic strength) to control protein aggregation states. By adjusting these parameters, the method transforms undetectable soluble misfolded proteins into detectable aggregated forms, enabling precise measurement. The aggregation process itself is driven by parameter optimization to maximize signal generation from minimal starting material.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides high specificity and sensitivity in distinguishing between PD and MSA, enabling early and accurate diagnosis, allowing for targeted treatment and improving patient quality of life.
Implementation Method 1
detecting via indicator fluorescence emission the misfolded αS aggregates
Data Source
AI summary
A method is provided for distinguishing between and/or diagnosing Parkinson's disease (PD) or multiple system atrophy (MSA) in a subject who is exhibiting symptoms associated with both PD and MSA. The method comprises: (A) contacting a biological sample obtained from the subject and comprising soluble, misfolded alpha-synuclein (αS) protein with a pre-incubation mixture comprising a monomeric αS substrate and an indicator to form an incubation mixture; (B) conducting an incubation cycle two or more times on the incubation mixture to form misfolded αS aggregates; (C) subjecting the incubation mixture to excitation and detecting via indicator fluorescence emission the misfolded αS aggregates; and (D) diagnosing the subject has having PD or MSA depending on the fluorescence emission intensity. In some aspects, the incubation cycles are conducted in the presence of a bead.